Medifast Inc

Medifast Inc(MED)股票分析

$12.180

+0.019 (+0.16%)收盘时

Loading chart…
High
12.450
Open
12.210
VWAP
12.16
Vol
107.69K
Mkt Cap
230.99M
Low
11.860
Amount
1.31M
EV/EBITDA, TTM
-55.85

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.

AI analysis of Medifast Inc (MED)

buy

Medifast Inc is a good buy right now due to its recent earnings performance and positive growth outlook. The current price is $12.18, with a forward P/E ratio of 12.48, indicating potential for future earnings growth. Additionally, the company reported a 34.29% price change following its last earnings announcement, reflecting strong investor confidence. However, the main risk is the projected loss per share of $0.35 for Q3 2026, which could impact investor sentiment.

Analyst Ratings (2)

Buy
1 Buy
1 Hold
0 Sell
Current: 12.18
最低
平均
最高

Stephens

2026-02-19

目标价

$12

Equal Weight

DA Davidson

2025-02-19

目标价

$17

Hold

DA Davidson

2024-11-05

目标价

$17

Hold

DA Davidson

2024-07-22

目标价

$18

Sell

DA Davidson

2024-06-05

目标价

$18

Sell

估值指标

The current forward P/E ratio for Medifast Inc (MED) is 12.48, compared to its 5-year average forward P/E of 10.18.

Forward P/E

Fair
5Y Average P/E
10.18
Current P/E
12.48
高估
76.13
低估
-55.77

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
3.73
Current EV/EBITDA
-55.85
高估
13.83
低估
-6.36

Forward P/S

Fair
5Y Average P/S
0.75
Current P/S
0.50
高估
1.13
低估
0.38

Alphio AI Price Scenarios for MED

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MED

$7.77

情景价格

B

Base

Base · 50%MED

$7.58

情景价格

B

Bear

Bear · 25%MED

$5.48

情景价格

事件时间线

2026-08-27 (ET)

09:00:00

Medifast Launches Metabolic Health Institute

2026-08-03 (ET)

19:30:00

Stock Futures Broadly Higher, Oil Prices Slip

17:00:00

Q2 Revenue at $76.4M, Down from $105.6M Last Year

17:00:00

FY26 Revenue Estimate Ranges from $270M to $300M

17:00:00

Sees Q3 Revenue of $60M-$80M, Estimate at $67.7M

资讯

MED FAQ — answered by Alphio AI

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources. It operates in the Consumer Non-Cyclicals sector (MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS industry).

Medifast Inc is a good buy right now due to its recent earnings performance and positive growth outlook. The current price is $12.18, with a forward P/E ratio of 12.48, indicating potential for future earnings growth. Additionally, the company reported a 34.29% price change following its last earnings announcement, reflecting strong investor confidence. However, the main risk is the projected loss per share of $0.35 for Q3 2026, which could impact investor sentiment.

2 analysts cover MED: 1 rate it Buy, 1 Hold and 0 Sell.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始